Last checked at 11 Sep 2012 10:38
For Immediate Release | 11 September 2012 |
ReNeuron Group plc
("ReNeuron" or "the Company")
Results of 2012 Annual General Meeting
Guildford, UK, 11 September 2012: ReNeuron Group plc (LSE: RENE) announces that all resolutions put to its shareholders at today's Annual General Meeting were passed.
- End -
Enquiries:
ReNeuron | +44 (0) 1483 302560 |
Michael Hunt, Chief Executive Officer | |
Dr John Sinden, Chief Scientific Officer
| |
Buchanan | +44 (0) 20 7466 5000 |
Mark Court, Fiona Henson, Sophie Cowles
| |
Cenkos Securities | +44 (0) 20 7397 8900 |
Stephen Keys, Adrian Hargrave (NOMAD and Broker) | |
Andy Roberts (Sales) |
About ReNeuron
ReNeuron is a leading, clinical-stage stem cell business. Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.
ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. ReNeuron's lead candidate is its ReN001 stem cell therapy for the treatment of patients left disabled by the effects of a stroke. This therapy is currently in clinical development. The Company is also developing stem cell therapies for other conditions such as critical limb ischaemia, a serious and common side-effect of diabetes, and blindness-causing diseases of the retina such as retinitis pigmentosa.
ReNeuron has also developed a range of stem cell lines for non-therapeutic applications - its ReNcell®products for use in academic and commercial research. The Company's ReNcell®CX and ReNcell®VM neural cell lines are marketed worldwide under license by USA-based Merck Millipore.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.